Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Survodutide for Adults with Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Findings from the SYNCHRONIZE-MASLD Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • August 25, 2026

Share

  • 1

    The article published in Nature Medicine has been corrected for several errors.

  • 2

    Juan M. Pericás and Michael Zimmerman were added to the author list with their respective affiliations.

  • 3

    Antonio Olveira's name and affiliation were corrected from “Antonio O. Martin” to his proper designation.

  • 4

    Rizwana Mohseni's second affiliation was also corrected in the article.

  • 5

    A numerical error in the treatment-discontinuation frequencies for the placebo group was amended.

Original Source(s)

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

  • August 25, 2026

Related Content

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min
Rates of hospitalization pre- and post-total pancreatectomy with islet autotransplantation for patients with pancreatitis

Author Correction: Low-protein diet enhances antitumor immunity in pancreatic cancer through microbiota-derived UDP-galactose